Reevaluation Prediction of the Effect Site Propofol Eleveld Model Using Slow and Fast Induction

NCT07237477 — Completed, 70 participants, Pablo O. Sepulveda

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Comparison of the Site Effect Model Prediction and BIS Predicted by Eleveld for Propofol in Slow and Rapid Inductions

RegistryNCT07237477, acronym fast or slow E
StatusCompleted
Study typeObservational
Enrollment70 (Actual)
SponsorPablo O. Sepulveda (Other)
ConditionsAnesthesia for Elective Surgery Patients, Anesthesia Brain Monitor, Pharmacodynamics
InterventionsEvaluation of the prediction of from the propofol PKPD model including in TCI pumps using fast (Effect site mode TCI) or slow (plasma TCI mode) induction (Drug)
Datesstart 2025-01-15, primary completion 2025-09-15, completion 2025-09-15, first posted 2025-11-19, last updated 2025-11-19
Locations1 site in Chile

Related Papers Related Patents Related Grants Related Experts
All trials for Anesthesia for Elective Surgery Patients All trials for Anesthesia Brain Monitor All trials of Evaluation of the prediction of from the propofol PKPD model including in TCI pumps using fast (Effect site mode TCI) or slow (plasma TCI mode) induction

-Summary

Patients ASA1-2, 18 to 70 years old, scheduled for elective surgery with personal conset to participate, will be randomised into two groups using different induction mode. TCI effect site mode induction or TCI plasma mode induction both using the Elevelt PKPD propofol model. Standard monitoring (EKG, SaO2, PCo2et, NIAP), and Conox/ and or BIS EEG monitor to evaluate the prediction.

The model's prediction will be compared with values provided by the Conox/BIS index for both groups and between them. The study will be conducted during the 20 minutes after Loss of responsiveness.

Expand all sections  ·  Collapse all

+Detailed description

Patients aged 18 to 70 years will be included. Patients allergic to propofol are excluded. Eleveld's PKPD model for propofol includes covariates for adjustment in administration with target-controlled infusion pumps. Induction to the site of effect will be performed using EC60 for each age, while slow induction will use the target plasma modality, starting at a target of 3 ug/ml and increasing by 0.5 ug/ml every 3 minutes until loss of consciousness. This is defined as the loss of response to voice and shoulder tap. The 20 minutes following loss of consciousness will be evaluated.

Biometric and gender characteristics of both groups, concomitant pathologies, and surgical times will be compared.

The temporal evolution of the propofol effect site predicted by the Eleveld model will be compared between the two types of induction using EEG (CONOX or BIS). To obtain the EEG index prediction by Eleveld it will be use the Tiva trainer software 2.0, simulating the evolution of the kinetics and effect site calculated by Eleveld in the infudion TCI pumps.

It is estimated that 20 patients per group are required to find a 20% difference in predicted versus actual EEG index with 90% power.

Statistical methods:

1. Data analysis tool: Stata 10 software
2. Statistics

* Summary: Mean (central tendency) and standard deviation (dispersion)
* Association: Student's t-test for continuous quantitative variables and Fisher's exact test for dichotomous variables.

+Arms and interventions

ArmTypeInterventionsDescription
Group 1: the prediction of the Eleveld propofol model in effect site mode TCI inductionDrug: Evaluation of the prediction of from the propofol PKPD model including in TCI pumps using fast (Effect site mode TCI) or slow (plasma TCI mode) inductionPatients ASA 1-2, 18 to 70 years, will be induced using propofol TCI in effect site mode EC60 of the Eleveld PKPD model and compared with the EEG CONOX behavior, If lost of responsiveness (LOR) was not reached, we climb up 0,5 ug/ml every 3 min. At LOR calculated effect site concentration will be used as reference to mantain anesthesia level.
Group 2: the prediction of the Eleveld propofol model in TCI plasma modeDrug: Evaluation of the prediction of from the propofol PKPD model including in TCI pumps using fast (Effect site mode TCI) or slow (plasma TCI mode) inductionPatients ASA1-2, 18-70 years, scheduled for elective surgery longer than 1 hour. Induced with TCI plasma mode using the Eleveld PKPD model. The infusion will begin using a target plasma of 3 ug/ml, and scale every 3 minutes in 0,5 ug/ml until Loss of responsiveness (LOR). At LOR the calculated effect site concentration will be used as reference to mantain anesthesia level. EEG (CONOX or BIS) will be used to evaluate the prediction of the model.
  • Evaluation of the prediction of from the propofol PKPD model including in TCI pumps using fast (Effect site mode TCI) or slow (plasma TCI mode) induction (Drug): Using TCI technology and EEG monitoring (CONOX) we will induce loss of responsiveness using the fast induction (Group 1) or slow induction (Group 2) and compare the prediction of the effect site model (PD) in each type of induction.

+Outcome measures

Primary outcomes

  • Prediction of the efect site propofol Eleveld model [The data will be retrieved directly from the infusion pumps and EEGs up to 20 minutes after the loss of clinical consciousness.]: The comparison betwen predicted and actual CONOX/BIS index will be made in two scenario: TCI effect site mode induction versus TCI plasma mode induction

+Eligibility

Sex: All, ages: 18 Years to 70 Years

Inclusion Criteria: patients ASA 1-2 scheduled for elective surgery, Exclusion Criteria: patients with psychiatric disorders, allergic to propofol, not giving their consent to participate

\-

+Locations (1)

FacilityCityCountryStatus
Hospital Base san José de OsornoOsorno, Los Lagos RegionChile

+Publications

  • Results publication: Coetzee E, Coetzee JF, Haasbroek M. Predictive pharmacodynamic performance of the Eleveld pharmacokinetic-pharmacodynamic model for propofol: comparison of predicted and measured bispectral index. Br J Anaesth. 2024 Oct;133(4):785-792. doi: 10.1016/j.bja.2024.06.041. Epub 2024 Aug 23. PMID 39179443

+Investigators

  • José Gonzalez Gonzalez, PHD, Study director, Departamento de Investigación Hospital osorno